Published in Clin Res Cardiol on June 19, 2011
Early reduction of therapy-resistant hypertension in a patient after single-sided renal denervation approach. Clin Res Cardiol (2013) 2.13
Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol (2013) 1.78
Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol (2011) 1.58
Carotid body denervation improves autonomic and cardiac function and attenuates disordered breathing in congestive heart failure. J Physiol (2013) 1.41
Acute changes in home blood pressure after the Great East Japan Earthquake among patients with chronic kidney disease in Fukushima City. Clin Exp Nephrol (2012) 1.40
Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism (2013) 1.27
Obesity-related metabolic syndrome: mechanisms of sympathetic overactivity. Int J Endocrinol (2013) 1.16
Renal sympathetic denervation: applications in hypertension and beyond. Nat Rev Cardiol (2013) 1.00
Effects of renal sympathetic denervation on post-myocardial infarction cardiac remodeling in rats. PLoS One (2012) 0.99
The projection and synaptic organisation of NTS afferent connections with presympathetic neurons, GABA and nNOS neurons in the paraventricular nucleus of the hypothalamus. Neuroscience (2012) 0.97
The biophysics of renal sympathetic denervation using radiofrequency energy. Clin Res Cardiol (2014) 0.96
Catheter-based renal sympathetic denervation significantly inhibits atrial fibrillation induced by electrical stimulation of the left stellate ganglion and rapid atrial pacing. PLoS One (2013) 0.93
Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension. Clin Res Cardiol (2015) 0.89
Testing a capacity-load model for hypertension: disentangling early and late growth effects on childhood blood pressure in a prospective birth cohort. PLoS One (2013) 0.87
Beneficial effects of renal sympathetic denervation on cardiovascular inflammation and remodeling in essential hypertension. Clin Res Cardiol (2014) 0.85
Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension. Clin Res Cardiol (2015) 0.83
Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. Clin Res Cardiol (2016) 0.82
Renal artery ablation instead of pulmonary vein ablation in a hypertensive patient with symptomatic, drug-resistant, persistent atrial fibrillation. Clin Res Cardiol (2012) 0.81
Functional neural-bone marrow pathways: implications in hypertension and cardiovascular disease. Hypertension (2014) 0.81
Short term fat feeding rapidly increases plasma insulin but does not result in dyslipidaemia. Front Physiol (2014) 0.79
Association of vitamin D status and blood pressure response after renal denervation. Clin Res Cardiol (2013) 0.78
Clinical application of interventional renal sympathetic denervation: recommendations of the Austrian Society of Hypertension 2012. Wien Klin Wochenschr (2012) 0.78
Renal Sympathetic Denervation for Treatment of Hypertension. Curr Treat Options Cardiovasc Med (2012) 0.77
Revisiting renovascular imaging for renal sympathetic denervation: current techniques and applications. Eur Radiol (2014) 0.77
Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation. Clin Res Cardiol (2015) 0.76
Neural regulation of the kidney function in rats with cisplatin induced renal failure. Front Physiol (2015) 0.76
Anemia is associated with an increased central venous pressure and mortality in a broad spectrum of cardiovascular patients. Clin Res Cardiol (2014) 0.75
Chronic Stress Facilitates the Development of Deep Venous Thrombosis. Oxid Med Cell Longev (2015) 0.75
Transcatheter therapies for resistant hypertension: Clinical review. World J Cardiol (2014) 0.75
Renal Denervation Suppresses the Inducibility of Atrial Fibrillation in a Rabbit Model for Atrial Fibrosis. PLoS One (2016) 0.75
Effects of renal sympathetic denervation on cardiac systolic function after myocardial infarction in rats. J Biomed Res (2015) 0.75
Device-Based Approaches to Modulate the Autonomic Nervous System and Cardiac Electrophysiology. Arrhythm Electrophysiol Rev (2014) 0.75
Nonblood/urine biomarker of progression of kidney disease in diabetes mellitus. Clin J Am Soc Nephrol (2015) 0.75
Effect of percutaneous renal denervation on blood pressure level and sympathetic activity in a patient with polycystic kidney disease. Clin Res Cardiol (2013) 0.75
Renal denervation: intractable hypertension and beyond. Cardiorenal Med (2014) 0.75
Novel strategies for treatment of resistant hypertension. Kidney Int Suppl (2011) (2013) 0.75
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet (2010) 14.40
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med (1996) 12.77
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet (2009) 10.53
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17
Cardiorenal syndrome. J Am Coll Cardiol (2008) 7.09
Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med (1984) 6.74
Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation (2008) 5.26
Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation (1990) 3.72
What causes sudden death in heart failure? Circ Res (2004) 3.44
Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension (2003) 3.29
Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med (2009) 2.97
Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation (2011) 2.88
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet (2010) 2.80
Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension (2011) 2.68
Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail (2007) 2.39
Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation (1986) 2.38
Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension (2010) 2.38
Nocturnal rostral fluid shift: a unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. Circulation (2010) 2.38
B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation (2009) 2.37
The cardiorenal syndrome: do we need a change of strategy or a change of tactics? J Am Coll Cardiol (2009) 2.09
Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation (2002) 2.02
The sympathetic system and hypertension. Am J Hypertens (2000) 1.90
Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol (2009) 1.88
Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens (2011) 1.80
The sympathetic nervous system and the metabolic syndrome. J Hypertens (2007) 1.80
Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J (2005) 1.80
The long QT syndrome: a prospective international study. Circulation (1985) 1.77
The 2009 Carl Ludwig Lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol (1985) (2009) 1.67
Sympathetic nerve activity in end-stage renal disease. Circulation (2002) 1.67
Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension. Am J Hypertens (2008) 1.60
Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension (1995) 1.53
Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens (2003) 1.50
Physiology in perspective: The Wisdom of the Body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol (2005) 1.50
Causes and consequences of increased sympathetic activity in renal disease. Hypertension (2004) 1.24
Differential associations between renal function and "modifiable" risk factors in patients with chronic heart failure. Clin Res Cardiol (2008) 1.22
Innervation of the renal cortex. Fed Proc (1978) 1.20
Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation (2003) 1.18
Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation (2011) 1.18
Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med (1990) 1.18
Diuretic therapy and resistance in congestive heart failure. Cardiology (2001) 1.17
Beta-blockers in chronic heart failure. Circulation (2003) 1.12
Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens (2002) 1.07
Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension (2005) 1.06
Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure. Am J Physiol Renal Physiol (2010) 1.05
Regional norepinephrine turnover in human hypertension. Clin Exp Hypertens A (1989) 1.05
Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats. Heart Vessels (2002) 1.00
Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant (2004) 0.99
Anxiety trait in patients with stress-induced cardiomyopathy: a case-control study. Clin Res Cardiol (2011) 0.98
Role of renal nerves in sodium retention of cirrhosis and congestive heart failure. Am J Physiol (1991) 0.96
Hypercapnic vs. hypoxic control of cardiovascular, cardiovagal, and sympathetic function. Am J Physiol Regul Integr Comp Physiol (2008) 0.95
Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. Br Med J (Clin Res Ed) (1986) 0.95
Renal sympathetic denervation: the jury is still out. Lancet (2010) 0.95
Effects of renal denervation on postprandial sodium excretion in experimental heart failure. Am J Physiol (1994) 0.92
Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens (1989) 0.91
[Interventional renal sympathetic denervation - a new approach for patients with resistant hypertension]. Dtsch Med Wochenschr (2010) 0.91
The hemodynamic link between insulin resistance and hypertension. J Hypertens (1991) 0.87
Renal denervation decreases blood pressure in DOCA-treated miniature swine with established hypertension. Am J Hypertens (1990) 0.86
Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol (1986) 0.84
Neurogenic factors and hypertension in chronic renal failure. J Nephrol (1997) 0.84
Renal nerves and hypertension: an update. Fed Proc (1985) 0.83
Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol (2001) 0.83
Dynamic arterial baroreflex in rabbits with heart failure induced by rapid pacing. Am J Physiol (1994) 0.82
Is elevated noradrenaline an aetiological factor in a number of diseases? Auton Autacoid Pharmacol (2009) 0.81
Randomized placebo controlled trial of furosemide on subjective perception of dyspnoea in patients with pulmonary oedema because of hypertensive crisis. Eur J Clin Invest (2010) 0.80
Role of the renal nerves in one-kidney, one clip hypertension in rats. Hypertension (1984) 0.80
Regional sympathetic effects of low-dose clonidine in heart failure. Hypertension (2003) 0.80
Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease. J Hypertens (2010) 0.79
Sleep-disordered breathing and heart failure: focus on obstructive sleep apnea and treatment with continuous positive airway pressure. J Card Fail (2009) 0.76
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet (2010) 14.40
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med (2005) 12.03
Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med (2012) 9.22
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med (2013) 7.35
Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet (2007) 6.88
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med (2010) 4.42
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci U S A (2005) 4.13
Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med (2006) 4.07
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol (2012) 3.56
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol (2005) 3.53
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation (2002) 3.48
Renin-angiotensin system and cardiovascular risk. Lancet (2007) 3.47
Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation (2013) 3.44
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34
Treatment strategies for resistant arterial hypertension. Dtsch Arztebl Int (2011) 3.32
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Update on myocarditis. J Am Coll Cardiol (2012) 3.12
Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med (2009) 2.97
Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation (2011) 2.88
Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation (2011) 2.87
Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation (2011) 2.71
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens (2009) 2.68
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press (2013) 2.62
Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. Heart Rhythm (2012) 2.60
Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation (2003) 2.59
Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol (2002) 2.54
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J (2011) 2.44
Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy. Arch Gen Psychiatry (2008) 2.43
Cardiomyocytes of noncardiac origin in myocardial biopsies of human transplanted hearts. Circulation (2002) 2.38
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol (2004) 2.29
Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med (2009) 2.28
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation (2005) 2.25
Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. BMJ (2012) 2.23
Renal denervation in moderate to severe CKD. J Am Soc Nephrol (2012) 2.21
Physical activity improves long-term stroke outcome via endothelial nitric oxide synthase-dependent augmentation of neovascularization and cerebral blood flow. Circ Res (2006) 2.21
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 2.20
Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med (2007) 2.20
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol (2009) 2.20
B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial. Ann Intern Med (2009) 2.18
Health-related quality of life after renal denervation in patients with treatment-resistant hypertension. Hypertension (2012) 2.17
Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J (2010) 2.12
Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk? J Hypertens (2007) 2.09
History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertension (2008) 2.09
Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation (2012) 2.07
Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur J Cardiovasc Prev Rehabil (2011) 2.05
Predictors of outcome in patients with suspected myocarditis. Circulation (2008) 2.03
Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study. Circulation (2009) 2.02
Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol (2003) 2.01
Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2007) 1.99
Pulsatile venoarterial perfusion using a novel synchronized cardiac assist device augments coronary artery blood flow during ventricular fibrillation. Artif Organs (2014) 1.99
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail (2005) 1.96
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol (2012) 1.94
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). J Am Coll Cardiol (2010) 1.94
Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol (2012) 1.93
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J (2012) 1.93
CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol (2012) 1.92
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA (2007) 1.91
Clinical service organisation for heart failure. Cochrane Database Syst Rev (2012) 1.90
Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J (2013) 1.90
Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol (2002) 1.89
Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J (2012) 1.89
Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol (2010) 1.88
A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol (2008) 1.85
Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther (2002) 1.84
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol (2013) 1.83
Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications. Pharmacol Ther (2010) 1.82